Both the compound and Uromodulin models demonstrated comparable net clinical benefit to the 48 h Δ SCr model at lower threshold probabilities (i.e., patients at a higher risk of pCSA-AKI with whom clinicians may prefer a “treat all” approach). This evidence concerns the gene UMOD and acute kidney injury.